Nanjing Vazyme Biotech Co Ltd (688105) — Cash Flow Reinvestment Rate

Latest as of September 2025: 0.21x

Nanjing Vazyme Biotech Co Ltd (688105) has a Cash Flow Reinvestment Rate of 0.21x as of September 2025, reinvesting CN¥15.83 Million (capex CN¥15.83 Million ) from operating cash flow of CN¥75.30 Million. Check 688105 cash flow quality score to evaluate the quality of earnings relative to operating cash generation.

Reinvestment Rate

0.21x
(Capex + Investments) / Operating CF

Total Reinvested

CN¥15.83 Million
Capex + Investments

Operating Cash Flow

CN¥75.30 Million
CNY

Capital Expenditures

CN¥15.83 Million
CNY

Nanjing Vazyme Biotech Co Ltd Cash Flow Reinvestment Rate (2019–2025)

Historical reinvestment intensity for Nanjing Vazyme Biotech Co Ltd across 6 annual periods. Explore cash flow to debt ratio of Nanjing Vazyme Biotech Co Ltd to assess how comfortably operating cash covers total debt obligations.

Annual Cash Flow Reinvestment Rate for Nanjing Vazyme Biotech Co Ltd (2019–2025)

Year-by-year capital reinvestment analysis for Nanjing Vazyme Biotech Co Ltd. For live market cap and broader valuation context, see Nanjing Vazyme Biotech Co Ltd market cap and net worth.

Year Reinvestment Rate Total Reinvested (CNY) Operating CF Capex YoY Change
2025 1.39x CN¥323.20 Million CN¥233.16 Million CN¥47.39 Million ▼ -75.7%
2023 5.71x CN¥1.13 Billion CN¥198.40 Million CN¥232.90 Million ▲ +119.3%
2022 2.61x CN¥1.92 Billion CN¥735.17 Million CN¥962.86 Million ▼ -4.9%
2021 2.74x CN¥1.69 Billion CN¥616.80 Million CN¥261.96 Million ▲ +102.8%
2020 1.35x CN¥1.09 Billion CN¥803.55 Million CN¥152.54 Million ▼ -36.0%
2019 2.11x CN¥32.08 Million CN¥15.20 Million CN¥19.88 Million
Cash Flow Reinvestment Rate = (ABS(Capex) + ABS(Investments)) / Operating Cash Flow